Software plays key role as Elekta presents product developments at ASTRO meeting

SAN FRANCISCO, September 15, 2014 – Speaking at Elekta’s Capital Markets Day in
San Francisco, during the 56th Annual Meeting of the American Society for
Radiation Oncology (ASTRO), Niklas Savander, President and CEO, restated his
strategic agenda for the
company (http://www.elekta.com/pressreleases/897884/elekta-presents-strategic
-agenda-to-outgrow-the-market.html), which includes a strong focus on software.
Savander told the audience: “We are not only leaders in radiation therapy
systems; we are also a leader in software solutions for the entire cancer care
continuum. Our hardware-agnostic treatment planning system and oncology
information system platforms are paving the way for an implementation of
Information-guided cancer care™ (http://www.elekta.com/information-guided).”

Niklas Savander reiterated that net sales is expected to finish at the lower
range of the 7-9 percent interval and that EBITA is expected to grow by
approximately 10 percent, both in local currency for the fiscal year 2014/15.

Todd Powell, Executive Vice President Software, explained Elekta’s software
vision: “Quite simply, we believe that better information will transform cancer
care. Elekta’s Information-guided cancer care solutions will integrate cancer
networks, people and information to enable clinicians to provide optimal care.”
He said Elekta is uniquely positioned to lead this field as it has had registry
solutions for the past 25 years; it has the largest, aggregated oncology
database on the market with more than two million patients.

Maurits Wolleswinkel, Executive Vice President
Neuroscience, mentioned that Elekta’s Leksell Gamma
Knife® Perfexion™ (http://www.elekta.com/healthcare
-professionals/products/elekta-neuroscience/gamma-knife-surgery/gamma-knife
-perfexion.html) won the Best in KLAS award for fourth consecutive
year (http://www.elekta.com/pressreleases/911615/for-fourth-year-in-a-row-elekta
-s-leksell-gamma-knife-perfexion-earns-top-rank-in-2014-s-best-in-klas-for
-radiation-therapy.html). He said: “At this year's ASTRO, Elekta is showcasing
its next generation intracranial radiosurgery solution as a work in
progress that will expand clinical versatility.” Wolleswinkel said that users
should expect improved fractionation possibilities and better options for image
-guided workflows. He also explained how Leksell Gamma Knife® Perfexion™
and Versa HD™ (http://www.versahd.com/) are uniquely complementary solutions for
stereotactic treatments.

Kevin Brown, Global Vice President Scientific Research, re-capped developments
of Elekta’s first-generation high-field MRI-guided radiation therapy system.
“Installation of the machine at UMCU, Utrecht is progressing well. Research on
the system was very well received at the American Association of Physicists in
Medicine meeting in July this year with several presentations by consortium
members (http://www.elekta.com/pressreleases/908118/the-christie-hospital-joins
-elekta-and-philips-research-consortium-to-develop-mri-guided-radiation-therapy
-system-for-cancer-treatment.html).” He also explained how bringing MRI directly
into the treatment room, can further improve treatment accuracy.

Presentations were also given by Jay Hoey, Executive Vice President North
America; John Lapré Executive Vice President Brachytherapy; and Dee Mathieson,
Senior Vice President Oncology Business Line Management.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 18:00 CET on September 15, 2014.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO:EKTAB. Website:
www.elekta.com.